Supportive Care Strategies for Dermatologic Toxicities Related to EGFR Inhibitor Therapies: 3-Part Knowledge Series-Session 2

Video Transcription

Video Summary

This ACCC Knowledge Series session focused on supportive care for dermatologic toxicities caused by EGFR inhibitor therapies, with an emphasis on triage, grading, treatment, and care coordination. The speakers reviewed how to assess baseline risk factors, perform thorough pre-treatment skin and nail exams, and educate patients that rashes and other skin effects are common, often appearing within the first two weeks of therapy. Preventive measures include daily moisturizing, sunscreen, protective clothing, and sometimes prophylactic antibiotics.<br /><br />The session then explained CTCAE grading for common toxicities such as acneiform or maculopapular rash, pustular eruptions, nail changes, paronychia, xerosis, pruritus, alopecia, photosensitivity, and ocular complications. Management strategies ranged from monitoring and topical treatments for mild reactions to oral antibiotics, steroids, retinoids, dose reduction, hospitalization, or specialist intervention for more severe cases. The presenters stressed early recognition of symptoms, patient-reported quality-of-life impacts, and prompt referral to dermatology, ophthalmology, podiatry, or surgery when needed.<br /><br />Finally, the discussion highlighted multidisciplinary care coordination through oncologists, advanced practice providers, nurses, pharmacists, and specialists, supported by electronic medical records and photo sharing. The overall goal is to keep patients on therapy while minimizing toxicity and preserving function and quality of life.

Keywords

EGFR inhibitor therapy

dermatologic toxicities

CTCAE grading

supportive care

acneiform rash

paronychia

patient education

multidisciplinary care